METHODS: Our observational case-cohort study will leverage the longitudinally phenotyped Fire Department of New York (FDNY)-WTC exposed cohort to identify Biomarkers of Airway Disease, Barrett\'s and Underdiagnosed Reflux Noninvasively (BAD-BURN). Our study population consists of n = 4,192 individuals from which we have randomly selected a sub-cohort control group (n = 837). We will then recruit subgroups of i. AHR only ii. GERD only iii. BE iv. GERD/BE and AHR overlap or v. No GERD or AHR, from the sub-cohort control group. We will then phenotype and examine non-invasive biomarkers of these subgroups to identify under-diagnosis and/or treatment efficacy. The findings may further contribute to the development of future biologically plausible therapies, ultimately enhance patient care and quality of life.
CONCLUSIONS: Although many studies have suggested interdependence between airway and digestive diseases, the causative factors and specific mechanisms remain unclear. The detection of the disease is further complicated by the invasiveness of conventional GERD diagnosis procedures and the limited availability of disease-specific biomarkers. The management of reflux is important, as it directly increases risk of cancer and negatively impacts quality of life. Therefore, it is vital to develop novel noninvasive disease markers that can effectively phenotype, facilitate early diagnosis of premalignant disease and identify potential therapeutic targets to improve patient care.
BACKGROUND: Name of Primary Registry: \"Biomarkers of Airway Disease, Barrett\'s and Underdiagnosed Reflux Noninvasively (BADBURN)\". Trial Identifying Number: NCT05216133 . Date of Registration: January 31, 2022.
方法:我们的观察性病例队列研究将利用纽约消防局(FDNY)-WTC暴露的纵向表型队列来确定气道疾病的生物标志物,巴雷特和未诊断的非侵入性回流(坏烧伤)。我们的研究人群由n=4,192个人组成,我们从中随机选择了一个子队列对照组(n=837)。然后,我们将招募i。AHR仅II的子组。只有GERDiii.BEiv.GERD/BE和AHR重叠或v.无GERD或AHR,来自亚队列对照组。然后我们将表型并检查这些亚组的非侵入性生物标志物,以鉴定诊断不足和/或治疗功效。这些发现可能进一步有助于未来生物合理疗法的发展,最终提高患者的护理和生活质量。
结论:尽管许多研究表明气道和消化系统疾病之间存在相互依存关系,致病因素和具体机制尚不清楚.常规GERD诊断程序的侵入性和疾病特异性生物标志物的有限可用性使疾病的检测进一步复杂化。反流的管理很重要,因为它直接增加患癌症的风险,并对生活质量产生负面影响。因此,至关重要的是开发新的非侵入性疾病标记,可以有效的表型,促进癌前疾病的早期诊断,并确定潜在的治疗目标,以改善患者护理。
背景:主要注册名称:“气道疾病的生物标志物,巴雷特和诊断不足的非侵入性回流(BADBURN)。“试验识别号:NCT05216133。注册日期:2022年1月31日。